Needham & Company analyst Stephen Unger downgraded Myriad Genetics (NASDAQ: MYGN) from Strong Buy to Hold.The analyst commented, "We are ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE